Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is expected to continue its trend of consistent growth and market share gains in the medical device industry, supported by strong earnings and organic revenue growth in Q1 2026. The company's focus on scale, market share, and operational discipline has resulted in increased profitability, debt reduction, and share repurchases, providing a positive outlook for future performance. However, as with any company, there are potential risks to consider, such as competition and staffing shortages, which should be monitored closely. Overall, GMED's continued expansion into international markets and commitment to product innovation make it a strong buy opportunity with potential for even higher growth in a bull case scenario.

Bears say

Globus Medical is facing several challenges that indicate a negative outlook on its stock. Despite EBITDA margin beating consensus and potential upside drivers such as faster spine market growth and higher Enabling Technologies sales, GMED's revenue growth is slowing, and its margins are expected to remain flat. Additionally, the company faces competitive pressure in its ExcelsiusGPS division, and its acquisitions may not provide sufficient value. Moreover, with the majority of voting power held by Chairman of the Board David Paul, there may be governance concerns for shareholders. Furthermore, our bear case scenario indicates a potential downside for the stock, and it is trading at a high P/E multiple.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Jun 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.